Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. by Jaarsma, T et al.
European Journal of Heart Failure (2020) POSITION PAPER
doi:10.1002/ejhf.2008
Self-care of heart failure patients: practical
management recommendations from the
Heart Failure Association of the European
Society of Cardiology
Tiny Jaarsma1,2*, Loreena Hill3, Antoni Bayes-Genis4,
Hans-Peter Brunner La Rocca5, Teresa Castiello6, Jelena Čelutkienė7,
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Self-care is essential in the long-term management of chronic heart failure. Heart failure guidelines stress the importance of patient
education on treatment adherence, lifestyle changes, symptom monitoring and adequate response to possible deterioration. Self-care is
related to medical and person-centred outcomes in patients with heart failure such as better quality of life as well as lower mortality
and readmission rates. Although guidelines give general direction for self-care advice, health care professionals working with patients with
heart failure need more specific recommendations. The aim of the management recommendations in this paper is to provide practical
advice for health professionals delivering care to patients with heart failure. Recommendations for nutrition, physical activity, medication
adherence, psychological status, sleep, leisure and travel, smoking, immunization and preventing infections, symptom monitoring, and
symptom management are consistent with information from guidelines, expert consensus documents, recent evidence and expert opinion.
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Introduction
Self-care is essential for patients with heart failure (HF), and
improving self-care is a major focus of multidisciplinary HF man-
agement programmes worldwide. Self-care can be defined as a
process of maintaining health through health promoting and pre-
ventive practices.1 Patients with HF and more effective self-care
behaviour have better quality of life and lower mortality and read-
mission rates than those with lower levels of self-care.2,3
Multidisciplinary management programmes that focused on
enhancing HF self-care significantly reduced HF and all-cause hos-
pitalizations in patients with HF.4 This is confirmed in an indi-
vidual patient data meta-analysis from 20 studies, representing
5624 patients with HF, that found a beneficial effect of self-care
interventions on time to HF-related hospitalization or all-cause
death and HF-related hospitalization alone and HF-related quality
of life.4
Although everyone (ill or healthy) is engaged in some level of
daily self-care, the need for self-care and the value of specific
guidance become more prominent once a person is diagnosed
with a complex chronic syndrome such as HF. Misunderstandings,
misconceptions, and lack of knowledge all contribute to insufficient
self-care, and thus patient education is vital.5
Self-care is an overarching concept formed of the three key
concepts of (i) self-care maintenance (e.g. taking or adjusting med-
ication as prescribed, engaging in physical activity, and adhering to
a healthy diet), (ii) self-care monitoring (e.g. regular weighing), and
Self-Care Maintenance: those 
behaviours used by persons
with a chronic illness to maintain 
physical and emotional stability.
• Restrict sodium when needed
• Restrict fluids when needed 
• Limit/refrain from alcohol
• When nutritionally deficient 
consider food supplements 
• Vaccination 
• Be physically active
• Take medication as prescribed
• Recognize mood disturbances 
• Maintain healthy sleep
• No smoking, no drugs
• Adapt travel and leisure if needed
Self-Care Monitoring: the process of 
observing oneself for changes in signs 
and symptoms
• Shortness of breath /dyspnoea
• Oedema
• Chest pain
• Decreased appetite /nausea





• Activity level 
• Weight
• Pulse, blood pressure 
• Need for support 
• Nutritional status 
• Fever, diarrhoea, vomiting 
• Feelings of depression, low mood
Self-Care Management response 
to signs and symptoms when they 
occur
• Adjust diuretics
• Adjust other medications
• Adapt activity level
• Adapt diet
• Ask for support
• Consult a health care professional
Figure 1 Self-care is an overarching concept based on three key concepts: (i) self-care maintenance (e.g. taking medication as prescribed,









































.. (iii) self-care management (e.g. changing diuretic dose in response
to symptoms) (Figure 1). For patients with HF it may be neces-
sary to regulate and adapt self-care during the disease trajectory,
e.g. during periods of deterioration, when comorbidities develop,
or when the patient requires more advanced therapies. In fact, at
the time of writing this manuscript the world is fighting against
the outbreak of COVID-19 (SARS-CoV-2 infection) by enforc-
ing social isolation and distancing which has disproportionately
affected patients with HF. In these circumstances, self-care mainte-
nance, monitoring and management are even more important than
usual to maintain HF stability and avoid deterioration of HF, which
can lead to preventable contacts with the health care system, such
as visits to the emergency room, visits to the general practitioner
and recurrent hospital admissions.
Most guidelines state very general recommendations related to
self-care behaviours. This is due to the lack of evidence on the
effectiveness of separate self-care behaviours or on the effect of
very specific recommendations, for example how often a person
should weigh him/herself. At the same time there are several
research studies and guidance documents that can help clinicians
guide treatment and discuss decisions with patients.
The aim of this paper is to summarise guideline recommenda-
tions, other relevant data and documents as well as expert opinion
related to HF self-care in order to provide practical management
guidance to health care professionals caring for patients with HF,
and to identify areas that require further research. This paper
serves as an update to previous
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Heart Failure Association (HFA) recommendations on self-care
published in 2011.6 We have updated and reshaped the 2011
document with research and recommendations published in
the past 10 years, developed sections on monitoring, travel
and leisure, smoking, and expanded the document to reflect
patient preferences related to self-care. In general, advice
related to self-care management is similar for patients with HF
with reduced ejection fraction (HFrEF), patients with HF with
mid-range ejection fraction (HFmrREF) and patients with HF with
preserved ejection fraction (HFpEF); however, when relevant,
we have added specific information for each ejection fraction
category in this version of the paper. The manuscript is orga-
nized in such a way that for each aspect of self-care, statements
from guidelines and additional evidence are summarized, advice
to patients provided, and professional attitudes outlined. Each
section concludes with recommendations for future research.
The recommendations are categorized into self-care behaviours
that help to maintain stability, monitor for changes, and respond
appropriately to symptoms. (We added a separate table (Table 1)
with advise to patients with heart failure regarding self-care, that
can be found in the end of this paper).
Self-care behaviour to maintain
stability
Maintain optimal nutritional status
Current guidelines and evidence
Body weight, obesity and cachexia
• Overweight is associated with deterioration in signs and symp-
toms of any type of HF, increasing left ventricular (LV) mass
and LV strain. Cachexia is related to poor prognosis and associ-
ated with end-stage HF. In the morbidly obese patient, bariatric
surgery can be offered to achieve at least 10% of weight loss
and positive LV remodelling.7–10 However, there are still con-
troversies about the ‘HF obesity paradox’, where the patients
with a higher body mass index (BMI), with confirmed diag-
nosis of HF, appear to have reduced mortality compared to
those with a lower BMI.11 Weight management in this large
sub-group of patients remains unclear. There is limited data on
the prognosis of HF patients with morbid obesity defined as
BMI ≥40 kg/m2; however, this group seems to have worse out-
come (overall increased mortality similar to underweight HF
patients); for this sub-group, a significant weight loss is impor-
tant and related to decrease major health risks. Most likely a
significant weight loss can be achieved by bariatric surgery.12
• Cachexia in HF is related to congestion, inflammation, malab-
sorption, anorexia, and neurohormonal over-activation, and as
a consequence is associated with increased mortality.9 In HF,
it has been usually been defined as unintentional oedema-free
weight loss of either >5% or as much as >7.5% in the preceding
6–12 months or BMI <20 kg/m2, with evidence of sarcope-
nia, wasting and abnormal biochemistry.10,13 Patients meet-



















































































.. team and receive optimized treatment, exercise advice, and
nutritional support.
Fluid and salt intake
• Fluid intake: Guidelines suggest that patients should limit fluid
intake to 1.5–2 L in severe HF to relieve symptoms, and
increase intake (and/or reduce diuretics) in hot and humid
weather or in case of fluid loss.14,15 Very limited data with
low level of evidence suggest that fluid restriction may reduce
the risk for HF hospitalization,16,17 whereas other reports
suggest it is not helpful for improving outcomes and is worse
for patients’ quality of life.16 Fluid restriction is believed to
be especially important in patients with hyponatraemia, but
in one observational study of hospitalized patients with HF
and hyponatraemia, fluid restriction was not associated with
a meaningful increase in serum sodium.18
• Salt intake: There is no robust evidence for benefits of limiting
salt intake in HF. In New York Heart Association (NYHA)
class III–IV HF, ingesting >3 g salt per day was associated
with increased risk of hospitalization and death19,20 whereas in
NYHA class I–II HF, an intake of <2 g salt was associated with
increased risk.19 Others describe that sodium restriction is
associated with increased risk of HF hospitalization.21 A recent
systematic review of nine trials involving 479 HFrEF patients
was inconclusive.22
Strict salt intake reduction is not recommended further
than the recommendation for the general population by the




• The relation between alcohol consumption and cardiovascular
(CV) disease is still controversial, even though the evidence
base for overall harm is increasing.23
• There is an association of alcohol consumption, especially binge
drinking, with supraventricular arrhythmias, especially parox-
ysmal atrial fibrillation which might precipitate, or worsen
HF signs/symptoms. Abstinence might decrease arrhythmia
burden.24
• Consuming more than the guideline-recommended alcohol
volumes (two units per day in men and one unit per day in
women) is associated with development of HF and therefore
it is recommended that this level of alcohol intake is not to
be exceeded. However, in alcohol-related HF, complete absti-
nence is advised, and if achieved is associated with significant
clinical improvement.14,25
Nutrients, food and vitamin supplements
• Guidelines suggest checking iron (ferritin and transferrin sat-
uration) levels to aid both in determination of the aetiol-
ogy of HF (iron overload), but also to guide whether iron
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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supplementation is required. Intravenous iron has been found
to improve quality of life, peak oxygen consumption and
exercise capacity and to decrease HF readmissions.14,26–28
Randomized controlled trials are ongoing investigating the
impact of intravenous iron supplementation on mortality and
hospitalizations.29 Whether increasing dietary iron supplemen-
tation has any benefits in HF remains unclear as oral treatment
was ineffective in increasing exercise capacity.30
• Hyperkalaemia occurs in up to 40% of patients with chronic
HF. Hyperkalaemia is associated with poorer outcomes and
with hospitalization and mortality in patients with HF and
should be corrected. Hyperkalaemia can be iatrogenic, caused
by concurrent drugs and nutritional/herbal supplements.31
• Deficiencies of specific nutrients (e.g. selenium, coenzyme
Q10, zinc, iron, protein, thiamine) are associated with HF.32
There is little evidence on the safe use of supplements.
Although inadequate intake and low plasma levels of micronu-
trients have been associated with adverse clinical outcomes,
evidence supporting benefit from therapeutic repletion is
limited. Thiamine (especially in alcoholics), and coenzyme
Q10 have the most clinical trial data for supplementation.33,34
Other than in patients who are deficient in specific
micronutrients, there is no clear role for routine micronutrient
supplementation as a component of HF management.10,32
Clinical practice and patients’ perspectives
Tailored advice for patients and their caregivers should be provided
considering their actual food and fluid intake, symptoms and
current medication use. Severely ill patients with HF with low
quality of life and decreased life expectancy should not be burdened
with extensive lifestyle changes which may be of limited benefit.
Professional attitudes and behaviour
• Do not judge others for their lifestyle choices or behaviour.
• Educate the patient on a healthy, varied diet. This can be done
by a team member of the HF team and specialist consultation
of a dietician might be needed.
• Because weight reduction may confer metabolic and functional
benefits, it is reasonable to recommend weight loss for selected
patients, especially if young, functionally limited by overweight,
and morbidly obesity (e.g. BMI >35 kg/m2). However, weight
loss may be especially challenging for patients and caregivers
already managing chronic HF.10
• Ask during every outpatient encounter about food intake.
It is reasonable for patients with HF to be screened for
unintentional weight loss at least annually, because of the strong
association between cachexia and adverse clinical outcomes. It
is important to detect early weight loss and loss of appetite.
Research primarily focused on cancer patients found that
identification of so-called ‘pre-cachexia’ and the provision of
tailored nutritional counselling, helped maintain nutritional
status, improve treatment tolerance and clinical outcomes.35
Such findings might be applicable to a HF population. Consider
regular (twice yearly) blood tests to check for iron levels and



















































































.. • Offer counselling to those who present with malnutrition or
alcohol dependency. Referral to nutritionist or dietician with
CV expertise should be offered to patients with cachexia,
morbid obesity, or unhealthy food intake. Consider referral
for support (addiction expertise) if the patient wishes to stop
drinking alcohol.
• Ask patients if they take any supplements (including vitamins)
and the rationale for it. Supplements have not been studied in
large randomized trials and the general recommendation is to
gain these micronutrients from a varied diet to prevent deple-
tion. Some supplements might be expensive, some contain high
levels of sodium or potassium without the patient and health
care provider knowing about it.
Recommendations for future research
• Weight management tailored for overweight patients with HF.
• Optimal fluid and salt management in patients with HF.
• The need for micronutrient supplementation in patients with
HF.
• Optimal dietary advice for cachectic patients
Optimize exercise tolerance and resume
sexual activity
Current guidelines and evidence
• Exercise training may improve functional capacity, quality of life
and reduce hospitalization.36
• Guidelines recommend regular physical activity and/or exercise
training, and specify that these are effective and safe in patients
with HF.14,25,37
• Extreme athleticism is associated with several distinct adverse
HF phenotypes, although direct causality is not established.38
• Sexual activity can be resumed for patients in NYHA class I
or II and for patients who are in NYHA class III or IV if their
condition is stable and optimally managed.39
Clinical practice and patients’ perspectives
Physical activity advice should incorporate patients’ views, prefer-
ences, needs and values.
Professional attitudes and behaviour
• Ask patients about physical activity and exercise tolerance as
part of routine clinical encounters.
• Refer to an exercise-based cardiac rehabilitation programme.
• Support and be empathetic if a patient struggles or is scared
of renewing exercise after diagnosis. Be aware that there are
many different forms of exercise, and involve your patient in
selecting which might be best.
• When selecting the exercise modality, the patient’s preferences
and abilities, age, concomitant diseases, leisure and working
habits, logistical restraints, and the availability of exercise train-
ing facilities and equipment should be taken into account.40 The
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Self-care of heart failure patients 5
EXPERT tool can be used for a standardized and yet individu-
alized training programme.41
• Training protocols need to be adapted to each patient
with regard to intensity (aerobic and anaerobic), type
(endurance, resistance, and strength), method (continuous
and interval), application (systemic, regional, and respiratory
muscle), control (supervised and non-supervised), and setting
(hospital/centre- and home-based).41
• Recognise problems with sexual activity, the relationship
between the patients’ sexual problems and HF and offer
pharmacological treatment for erectile dysfunction or spe-
cialist referral when necessary. Inform patients about energy
consumption/exercise tolerance, and about the relationship
between sexual problems and HF. Consider to involve the part-
ner in these discussions.
Recommendations for future research
• Exercise programmes for specific HF populations such as
patients with HFpEF, the very elderly, cachectic or frail patients.
• Role of effects of telerehabilitation in promoting exercise
performance in patients with HF.
Optimize adherence to medication
Current guidelines and evidence
• The reasons for non-adherence are multifactorial and effective
interventions include improving understanding of the benefits
of HF medication and self-care, as well as access and trust in
their provider and health system.42
• Patients who are non-adherent have significantly increased
rates of hospitalization and decompensation.43
• Guidelines recommend the provision of patient education with
a particular emphasis on adherence and self-care.14
• Depression,42 frailty44 and cognitive decline45,46 are clinical
factors that can affect adherence.
• Family members and informal caregivers have an important role
in improving adherence to self-care.47,48
Clinical practice and patients’ preferences
Many patients and family members demand and appreciate shared
decision-making and health education. A respectful relationship is
needed to optimally address adherence.49 Polypharmacy should be
carefully assessed and priority (survival, quality of life, symptoms,
side effects) should be discussed with patients and caregivers. In
patients with comorbidity, optimize drug use. For drugs with sim-
ilar pharmacodynamic actions, give preference to evidence-based
medication in target dose instead of combination therapy.
Professional attitudes and behaviour
• Avoid as much as possible polypharmacy.
• Provide written and verbal information on indications, benefits,



















































































.. such as optimal time schedule, what to do in case of missed
dose, etc. This needs to be adapted to the needs of patients,
their level of understanding and their preferences. Consider
involving caregivers if the patient is agreeable and consents.
• Members of the HF team must be aware that several differ-
ent factors affect adherence,45 including polypharmacy asso-
ciated with comorbidities, taking multiple doses per day, age,
cognitive issues, patient’s understanding, addiction and poor
social support.50
• Check if the patient understands the role of each medication in
their treatment, ask if they are taking their medications and ask
if there are possible barriers for medication taking as a routine
part of each clinical encounter. Discussing pharmacy records
(if patients collect their prescription) might be an option to
discuss possible barriers to adherence.
• Consider referral to other health care providers (e.g. psychol-
ogist, general practitioner, HF pharmacist) if necessary. Involve
the multidisciplinary team in management plans in patients with
complex comorbidities, including the general practitioner.
Recommendations for future research
• Approaches to improve monitoring and improving medication
adherence including eHealth.
Optimize psychological status
Current guidelines and evidence
• A lot of patients with HF symptoms (NYHA class II–IV) suf-
fer from anxiety and depression. The rate of patients with
HF and depressive symptoms escalates to nearly 70% during
hospitalization.51 Depressive symptoms and anxiety might have
consequences for other self-care behaviours (e.g. exercise,
adherence), involvement in decision-making, and for family
dynamics.52 Depression is an independent risk factor for
increased use of health care resources, with severe symptoms
associated with increased mortality and hospitalizations.51,53
• Good psychological support is important to both patients and
families.14
• Depression is associated with increased risk taking behaviour,
poor adherence and social problems.54
• A systematic review and meta-analysis of 19 randomized con-
trolled trials (3447 patients) demonstrated the benefit of
exercise on wellbeing.55
• Antidepressants are safe in patients with HF and are not asso-
ciated with increased mortality. However, there is inadequate
evidence that the use of antidepressants effects significant
improvement in depression or cardiac outcomes.56,57
• Interventions, such as Tai-Chi, yoga, meditation, relaxation, and
stress management may improve quality of life and psycholog-
ical status.58–60 Cognitive behavioural therapy has been found
to decrease depressive symptoms in patients with HF.61,62
• Family-based education can improve quality of life at 3- and
6-month follow-up.47
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Clinical practice and patients’ perspectives
Living with HF can be stressful and challenging, and patients often
report mental distress such as anxiety and depression.63
Professional attitudes and behaviour
• Screen for anxiety and depression. Consider using self-
reported questionnaires to assess mental health accurately
and identify problems.
• Involve family (if agreed by the patient).64
• Regularly communicate information on disease, treatment
options and self-care (e.g. exercise) and motivate patients
to participate in non-pharmaceutical management, such as
exercise, mindfulness, etc.
• Consider referral for psychiatric/psychological input as
necessary.
• Ask the patient about work and financial concerns aggravating
psychological responses; these could be remedied if the patient
is eligible for benefits.
Recommendations for future research
• Optimal screening for and management of depression and
anxiety in patients with HF.
Optimize sleep
Current guidelines and evidence
• Patients with HF often experience unsatisfactory and insuffi-
cient sleep (in quality and time) due to periods of pulmonary
fluid overload resulting in orthopnoea, paroxysmal nocturnal
dyspnoea and nocturia.65
• Psychological problems (anxiety, depressive mood) and obe-
sity are commonly associated with insomnia in patients
with HF.
• Studies suggest that almost 75% of patients with HF report
sleep disturbance and poor sleep quality, with 44% reporting
restless sleep and 41% having trouble falling asleep. Moreover,
39% experience early awakening and 32% have trouble return-
ing to sleep after early or brief night awakenings.66–68
• Poor sleep quality may impact the ability of patients with HF to
adequately perform self-care.69,70
• Sleep-disordered breathing affects over 50% of the patients
with HFrEF.65 As HF becomes more severe, the prevalence
of Cheyne–Stokes respiration with central sleep apnoea
(characterized by an oscillatory pattern of ventilation with
hyperventilation-induced hypocapnia) increases markedly.71
The other main type of sleep disorder prevalent in patients
with HF is obstructive sleep apnoea (OSA). OSA is particularly
common if the patient is overweight, diabetic, or has a large



















































































.. OSA is also regarded as one of the contributing comorbidities
in HFpEF.
• Positive pressure mask therapy (CPAP) may be considered in
HF and OSA. There is some evidence that the treatment of
OSA in patients with HF with CPAP can improve symptoms,
cardiac function, biomarkers of CV disease and quality of
life, but the evidence for an improvement in mortality is
weak.65
• Patients with HFrEF and predominantly central sleep apnoea
should not receive adaptive servo-ventilation because it can
lead to a higher death rate.71
Clinical practice and patients’ perspectives
Problems with sleeping should be part of clinical assessment, and
underlying causes, such as fluid overload, OSA or psychological
problems such as anxiety and depression, should be diagnosed and
addressed with an intervention.
Professional attitudes and behaviour
• Be aware that insomnia may cause significant mental and
physical health problems. Routinely ask for the nature and
quality of sleep. Check if patients are feeling rested after sleep.
• When patients describe sleep disorder, check if patients are
euvolaemic.
• Perform appropriate depression and anxiety scores and con-
sider referral for psychiatric/psychological input as necessary.
• Consider asking the partner of the patients about sleep prob-
lems. They might report that the patient snores, has sleep
apnoea or exhibits daytime sleepiness, although the latter may
be infrequent due to sympathetic stimulation.73
• Where sleep-disordered breathing is suspected, perform a
formal sleep study to confirm the diagnosis and type of apnoea.
• In the presence of OSA, provide advice on weight reduc-
tion/control (if relevant) and advocate for the regular use of
CPAP for at least 6 h per night. Consider and carefully dis-
cuss the benefits and deleterious effect of sleep medication.
Benzodiazepines are generally discouraged due to the possibil-
ity of tolerance and addiction. In older adults, benzodiazepines
can impair cognition, mobility, and driving skills and increase
the risk of falls. Antihistamines are safe but can cause daytime
sleepiness. There is no evidence regarding the use of melatonin
in HF. Zopiclone is used more frequently and is generally con-
sidered safer than benzodiazepines.74,75
Recommendations for future research
• Effects and long-term clinical consequences of use of sleep
medications in patients with HF.
• Determinants of sleep quality in patients with HF and associa-
tions with comorbidities.
• Interaction of sleep quality in patients with HF and ability to
self-care.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Adapt travel and leisure
Current guidelines and evidence
• Air travel: There is an increased incidence of CV events during
travel for persons who have existing CV disease,76 with cardiac
causes representing 8% of medical emergencies during air
travel.77 Among cruise ship passengers, HF decompensation
represents approximately 4% of CV emergencies.78 Moreover,
patients with HF are at higher risk of developing deep vein
thrombosis and pulmonary emboli during long haul flights.79,80
• Passengers with stable HF, without recent changes in symptoms
or medications, are usually able to tolerate air travel and the
associated mild hypoxia.79,81,82
• For patients with stable HF including NYHA class III and IV,
hypoxia up to 1 h at rest produces no significant deleterious
effects.81,83 Take care of pulmonary hypertension, even if the
NYHA class is low. Periods of up to 7 h (long haul) are
tolerated by those with mild to moderate stable HF (NYHA
class II).84 Severe decompensated HF poses serious challenges
to air travel.85
• Change in climate: Colder climates can increase peripheral
vascular resistance and thereby increase myocardial oxygen
demand, making it easier to reach the ischaemic threshold
resulting in and worsening anginal symptoms for patients with
ischaemic cardiomyopathy.6
• Altitude: Depending on NYHA class, patients may safely reach
high altitude of up to 3500 m (NYHA class I–II) or 3000 m
(NYHA class III). Being at high altitude, no greater intensity
than moderate physical activity is recommended. It is prudent
not to exceed an ascent rate of that recommended for healthy
travellers (300–500 m/day when above 2500 m).86
• Stay abroad: Travel also may be associated with a change in
lifestyle related to food and alcohol intake and diuretic dose
may need adjustment to avoid decompensation.
• Gastro-intestinal upset is quite common when a patient is
exposed to alien bacterial flora, which, coupled with sweating
in hot climate, may cause dehydration. A practical individualized
advice might include to reduce or stop diuretics, drink an
additional 500–1000 mL of non-alcoholic drinks and if the body
weight is back to normal the patient can restart the usual
medicines. Some patients might even be advised in case of
weight loss and/or symptomatic hypotension, to temporary
reduce the doses of the diuretics and/or angiotensin-converting
enzyme inhibitors/angiotensin receptor blockers/angiotensin
receptor–neprilysin inhibitors.
• Driving: The Driving Licence Committee of the European
Union amended its Directive 2016/1106 of 7 July 201687 and
states that driving licences may be issued to or renewed for
applicants or drivers in NYHA class I, II, III (if stable) for
motor cycles, passenger cars and other small vehicles with
or without a trailer (group 1). Driving licences shall not be
issued to or renewed for applicants or drivers in NYHA
class IV.
Related to professional driving or heavy vehicles [vehicles



















































































.. than nine passengers (including the driver)] (group 2), drivers
in NYHA class I and II, driving licences may be issued or
renewed provided that the LV ejection fraction is at least 35%.
Driving licences shall not be issued for professional driving
or heavy vehicles to NYHA class III and IV. Other condi-
tions such as syncope, arrhythmia and treatment should be
considered.
Clinical practice and patients’ perspectives
Many patients with HF are keen to travel, both for business and
leisure. Education, planning and access to timely review when
necessary are important to help avoid anxiety and ensure the
possibility of safe travel.
Professional attitudes and behaviour
• Inform and discuss medical and practical issues related to travel.
• A clinicians advice regarding a patient’s fitness to drive should
include consideration of the patient’s level of knowledge and
insight into their medical condition, ability to manage the con-
dition, adherence to prescribed treatment and ability to modify
driving activities to accommodate their medical condition.88
For patients in NYHA class I, II or III no restriction (if not
complicated by syncope, arrhythmia or other diseases and
treatment) for driving is needed for private transportation. For
professional driving, additional rules apply (patients must be in
NYHA class I or II and LV ejection fraction ≥35%).87
Recommendations for future research
• Do HFrEF and HFpEF patients have similar physical adaptations
to travel?
• What are the effects of long-distance car/coach/air travel in
patients with HF?
Immunization and preventing infections
Current guidelines and evidence
• Influenza infection is an important trigger for CV events.89
• Patients with HF are vulnerable to viral infections (like the
recent COVID-19).
• Influenza vaccination is associated with a significant decrease in
all-cause mortality risk in patients with HF, as recently shown
in a meta-analysis of 179 158 patients which included patients
with HF.90
• Guidelines advise yearly immunization against influenza and a
one-time only vaccination against pneumococcal disease.14
Clinical practice and patients’ perspectives
Importance of vaccination needs to be discussed in an open manner
and worries of patients and families should be discussed.
Professional attitudes and behaviour
• Discuss benefits and possible barriers.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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• Advise on local immunization practice, routines, and reim-
bursement.
Recommendations for future research
• Optimal intervention to protect patients with HF from infec-
tion and its complications.
Refrain from smoking and drugs
Current guidelines and evidence
• Professional HF guidelines recommend that patients should be
counselled to avoid smoking as well as illicit drug use.14,91
• Use of e-cigarettes is not advised as there is signifi-
cantly higher risk of CV diseases among dual users of
e-cigarettes + combustible cigarettes compared with smoking
alone.92
• Waterpipe use exposes smokers to significantly higher levels
of heavier and more toxic polycyclic aromatic hydrocarbons
than cigarette smoking, as well as cardiorespiratory toxicants
such as volatile organic compounds and heavy metals such as
cadmium and lead that can injure the blood vessels and the
brain.93
• Cocaine, amphetamine, ‘ecstasy’, cannabis, lysergic acid diethy-
lamide (LSD), psilocybin (‘magic mushrooms’), volatile sub-
stance, narcotics, all can induce major acute changes in CV
function, and may also cause irreversible damage to the
heart.25,94
Clinical practice and patients’ perspectives
Although it seems obvious to professionals that patients with
HF should not smoke or use illicit drugs and they may assume
that patients quit after their cardiac diagnosis, a lot of patients
with HF are active smokers (13–54% patients).95 Engaged,
patient-centred smoking and drug cessation counselling requires
health professionals to listen to patients early in the process.
Patients desire honest, consistent, and pro-active discussions and
actions.96
Professional attitudes and behaviour
• Ask patients about tobacco use, e-cigarette use, waterpipe
(Hookah/Shisha/Hubble bubble) and use of recreational drugs
as part of routine clinical encounters.
• Associated psychosocial issues often occur alongside drug
abuse and should also be considered.
• Consider referral for support if the patient wishes to stop
smoking or taking drugs.
• Become familiar with the principles and practice of cessation,
including the use and prescription of validated pharmacother-
apies in case of smoking cessation (nicotine replacement ther-
apy, such as bupropion, varenicline) with caution for CV side



















































































.. • Provide clear, concise, unambiguous, and non-judgemental
advice regarding the importance of cessation and offer specific
assistance (e.g. cognitive behavioural therapy and psychological
support) in initiating a cessation attempt.1,97
• Be aware that illicit drug use and smoking preclude heart
transplantation.
• Be aware that illicit drug use is often associated with signif-
icant social issues (e.g. homelessness) with associated con-
comitant lack of adherence and engagement with health care
teams.
Recommendations for future research
• Risks and prevalence of recreational drugs in patients
with HF.
Self-care behaviour to monitor
for changes
Deterioration of HF or development of new symptoms can be dev-
astating for patients, significantly affects quality of life and worsens
outcomes. Numerous studies have investigated self-management,98
but none specifically self-monitoring. No specific programme char-
acteristic is clearly associated with better outcomes.99 Still, most
self-management programmes include self-monitoring.100 Monitor-
ing should include signs and symptoms of HF, of comorbidities and
of side effects of medication.101
Symptom monitoring (self-monitoring
and telemonitoring)
Current guidelines and evidence
• Guidelines recommend monitoring of signs and symptoms
of HF as an integral part of self-care.14 Monitoring may be
undertaken by the patients themselves, in person by clinicians,
by remote monitoring (with or without implanted devices)
including structured telephone support.14
• Several meta-analyses have suggested clinical benefits from
remote monitoring.102 The TIM-HF2 study demonstrated
prognostic improvement in the context of a 24/7 support
system.103
• Monitoring using implantable devices may improve out-
comes. This includes remote monitoring of pulmonary
artery pressure using the CardioMEMS device104 or multi-
parameter monitoring based on implantable cardioverter-
defibrillators.105
Clinical practice and patients’ perspectives
Early detection of a deterioration in HF symptoms is important
in order to prevent hospital admission and increased mortality.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Patients should receive education in symptom monitoring at diag-
nosis, with a management plan discussed and agreed on how this
could be safely and effectively delivered in the future. Monitoring
over the course of the patients’ lifetime can be done in a variety
of ways, with patient preference and resource availability directing
choice. The current COVID-19 pandemic has ensured a renewed
focus on remote monitoring.
An easy guidance to help patients with HF to monitor themselves
is depicted in Figure 2. The frequency of monitoring should depend
on clinical status and stability. The monitoring interval should be
short (e.g. days) if the clinical condition or medication has been
changed, but is needed for at least every 6 months for patients
with stable HF.106 However, evidence is lacking to support these
recommendations.
Professional attitude and behaviour
• Arrange for reading support (e.g. reading the weighing scale




























. necessary, e.g. from a family member, home care or the HF
team.
• Recognize changes and know how and when to contact a health
care professional.
• Call the HF team if you are acutely unwell with diarrhoea
and/or vomiting that persists more than one day.
• Consider support by informal caregivers if the patients prefer.
• Consider using telemonitoring.
• Be aware that patients have different degrees of both health
literacy and technology and computer skills and that conse-
quently there is no single way a group of patients should be
monitored. Help patients to assess symptoms and to react
appropriately. Consider the need to assess:
◦ Frequency (how often)
◦ Intensity (e.g. on scale 1–10)
◦ Rate (on how many occasions during a time interval)
◦ Duration (how long)
Figure 2 Guidance for self-care monitoring and self-care management of patients with heart failure (HF). GP, general practitioner.
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◦ Pattern (mornings, after activities, etc.)
◦ Specificity of the symptom (e.g. pain in the whole body, arms,
etc.).
• Telemonitoring may be considered to support patients in
self-monitoring, though best practice is not yet defined. Sev-
eral digital health applications are available to monitor symp-
toms and patients may want to use them to keep track of
their symptoms and share the data with health care profes-
sionals. It should be an integral part of care, but the best
approach is not yet defined and may vary among patients
(Table 3).
Recommendations for future research
• Transition from a face to face review with the HF team to joint
virtual/face to face service.
Monitor side effects, adverse effects and
complications
Current guidelines and evidence
• Adverse effects and side effects of HF medications are doc-
umented as high as 10% in clinical trials and up to 17–22%
in observational studies.107,108 Side effects commonly lead to
non-adherence to HF treatment, but up to one-third of patients
experiencing such problems do not inform their health care
providers.108 It can be difficult for both patients and health care
professionals to separate disease symptoms from drug-related
side effects.109
• Professional HF guidelines strongly recommend education of
patients of the common side effects of HF medications.14,15
Provision of information on adverse reactions is suggested, as
well as counselling about when to notify health care profession-
als about drug-related symptoms.
• Patients who report on side effects are described to have lower
general health perceptions, stronger general beliefs about
medication overuse, having neurotic personality, are more
often female and in higher NYHA functional class.108,110–112
• The concern about medication-attributed hypotension is fre-
quently exaggerated among both patients and clinicians. Impor-
tantly, asymtomatic hypotension is no reason to reduce medi-
cation or to avoid up-titration in patients with HFrEF. On the
other hand, evidence suggests intensive blood pressure control
in older persons compared with standard treatment does not
exacerbate orthostatic hypotension and does not increase the
risk of injurious falls.113
• Initial data on the use of eHealth tools for patient
self-monitoring show significant increases of positive changes
in medication use; however, currently there is little or no
evidence to support their effectiveness for identification of
side effects or improving patient satisfaction.114
• Renal function changes are often considered an adverse reac-



















































































.. HFrEF; however, up to date evidence shows that mortality ben-
efits are maintained despite worsening renal function.115
Clinical practice and patients’ perspectives
Almost half of the patients with HF consider medication side effects
to be a serious challenge caused by this disease and believe that
health care professionals can prevent, alleviate, or control these
adverse reactions. Clear advice about rationale for use, possibility
of modification and shared decision-making can help to cope with
adverse effects, which highlights the importance of an open and
effective relationship between the patient and the health care
professional.
Professional attitudes and behaviour
• Adjust the medication regimen in case of side effects, explain
the reasons and share with the patient an informed decision
about how to cope with the side effect.
• Counsel all patients and their preferred caregivers to recognize
and act upon common side effects of HF medications.
• Advise patients to seek medical help immediately in case of
swelling lips or throat.
• Counsel patients on how to reduce risk of falls.
• Start HF medications at a low dose and increase in small steps
to improve tolerance.
• Rule out pulmonary congestion and heartburn as a cause of
cough prior to discontinuing angiotensin-converting enzyme
inhibitors.
• Recommend patients not to skip the diuretic therapy when
they are away from home, but encourage them to choose the
optimal timing of taking the diuretics according to their peak
urination and planned trip, for example, upon returning home.
• Help patients to document a history of side effects.
• Be aware that associated colleagues might need an explanation
in terms of worrisome blood pressure or renal function.
• Report the adverse event in the patient’s records.
Recommendations for future research
• Strategies to prevent and/or reduce the frequency of
drug-attributed side effects.
Self-care Management behaviour
Self-care behaviour to respond
appropriately to symptoms
Appropriate responses to symptoms include patients adjusting
their diuretic dose, contacting a health care provider, and decreas-
ing activity level as well as fluid and salt intake.
Current guidelines and evidence
• HF guidelines recommend diuretics to improve symptoms and
exercise capacity in patients with signs and/or symptoms of
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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congestion, and they should likewise be considered to reduce
the risk of hospitalization in these same patients.14
• A flexible and individualized diuretic dosing regimen may
improve quality of life and help reduce emergency depart-
ment visits and HF-related hospitalizations in patients with
HFrEF.116
• Despite the guideline recommendation to use the lowest
possible dose of diuretics and discontinue loop diuretics
if possible, little information is available on discontinu-
ing loop diuretics in contemporary treated patients with
HF.117,118
• Adjustment of diuretic therapy (often an increase) may improve
outcomes.104
Clinical practice and patients’ perspectives
Reactions to symptoms need to be adapted to the individual
patient. Due to changes in the patients’ condition (either HF
related to other reasons) the medication regimen might need to be
changed (see part on side effects and medication), physical activity
level and exercise training decreased, or a (temporary) change in
their sodium or fluid intake needed.
Furthermore, diuretic therapy is used to treat signs and/or
symptoms of congestion.
The goal of diuretic therapy is to achieve and maintain
euvolaemia with the lowest achievable dose. However, clinical
assessment of euvolaemia may be difficult and many patients
remain congested despite increase in HF therapy.119 The dose
of the diuretic must be adjusted according to individual needs
over time. A patient-directed flexible diuretic dosing schedule
based on personalized variation in fluid-related signs and symp-
toms is safe in patients with chronic HF. Some patients and
families might not feel comfortable making decisions to change
medications or lifestyle and need support from the health care
providers.
Professional attitudes and behaviour
• Provide individualized information to support self-care man-
agement to patients and caregivers. Patients may adjust diuretic
therapy and/or alert their health care team in case of increasing
signs and symptoms (e.g. dyspnoea, oedema, hypotension), or
a sudden unexpected weight gain of >2 kg in 3 days as a rule of
thumb; however, this may need to be tailored to the individual
patient.
• In selected euvolaemic/hypovolaemic patients, the use of a
diuretic drug might be (temporarily) discontinued.
• In patients with severe generalized congestion, especially in
those with gut oedema, the effect of oral furosemide may
be altered due to inadequate gastro-intestinal absorption. A
change in diuretics or a switch to intravenous furosemide is
recommended in order to increase diuresis, reduce generalized
congestion and gut oedema and re-establish gastro-intestinal
absorption for oral diuretics.
• Renin–angiotensin–aldosterone system inhibitors and



















































































.. significantly increase the risk of acute kidney injury and/or
hyperkalaemia. One or more of these agents may need to be
temporarily stopped or its dose reduced during illness. Partic-
ularly the diuretics and mineralocorticoid receptor antagonists
migth need to be reduced/temporarily stopped (early).
Recommendations for future research
• Indication and consequence of flexible diuretic dosing
strategies.
• Decision-making about how to manage particular symptoms.
Concluding remarks
This paper aimed to summarize practical recommendations that
can help to improve self-care behaviour in patients with HF.
Self-care is very important to improve patient outcomes, including
quality of life and lower mortality and readmission rates. How-
ever, despite the obvious relationship between good self-care and
positive health outcomes, many patients find it difficult to adhere
to self-care advice, probably due to lack of motivation, ability
or support. Health care professionals have an important role to
inform patients, teach skills, adapt information, support individual
needs and abilities and to engage with patients to make shared
decisions.
Self-care is not meant to be synonymous with ‘doing it all by
yourself ’. Informal caregivers, such as family or friends, can be
involved if the patient prefers in all aspects of self-care (mainte-
nance, monitoring and management) and this should be recognized
by health care professionals. Materials and tools that can be used
to support self-care are numerous and although the presentation
of those is outside the scope of this document, we would like to
specially mention the website ‘heartfailurematters.org’, that has a
dedicated section on self-care behaviour.120
Measurement of HF-related self-care behaviour is advised when
testing behavioural change interventions, for example with the
9-item European Heart Failure Self-care Behaviour scale121,122 or
the 29-item revised Self-Care of Heart Failure Index.123 These
questionnaires are valid and reliable to measure HF self-care
behaviour and are available in several languages and used in research
studies and can be considered to use in clinical practices to
guide patient education. In addition, there is room to improve
measurement of symptoms and factors related to self-care with
valid and reliable instruments.
In this paper we have reviewed the specific self-care behaviours
needed for most patients with HF. However, most patients have
several comorbidities that can affect the self-care behaviour
required (e.g. which diet to adapt, which symptoms to monitor)
and also affect their ability to change behaviour (e.g. depression
might hinder physical activity and decrease adherence to medica-
tions) or to implement advice (e.g. in case of cognitive problems). In
addition, factors for example cultural aspects, economic restraints,
and access to care need to be considered when giving advice on
self-care behaviours.124
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Table 1 Advise to patients with heart failure regarding self-care
Self-care maintenance
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Maintain optimal nutritional status
- If you have a body mass index >35 kg/m2 consider weight reduction since this might improve your functional capacity and quality of life. Please
consult a dietician if possible. The general recommendation is to promote healthy lifestyle and weight loss, preferring plant-based food (fruit,
vegetable, seeds, nut, legumes, whole grain cereals) over animal-based, processed foods and added sugar. Among animal-based aliments, fish
and fermented dairy should be preferred over meat, minimizing the intake of red meat.
- Unintentional weight loss may be a sign of deteriorating heart failure and impending cachexia and should be brought to your health care
providers’ attention.
- Avoid excess of salt intake, that is keep <5 g a day (just under a teaspoon). This can be done by not adding salt during the preparation of food;
not having a saltshaker on the table; limiting the consumption of salty snacks and choosing products with lower sodium content.
- Avoid large amounts of fluid intake. Adapt fluid intake in times of high heat and humidity, nausea/vomiting.
- Limit alcohol intake to two units of alcohol per day if you are a man and one unit if you are a woman, or no intake if alcohol has caused or
contributed to your heart failure.
- In case of nutrient or vitamin deficiencies, supplementation may be considered, but there is no clear role for routine micronutrient
supplementation. Some ‘natural’ or herbal supplements may interact with medication or might be high in potassium. Seek advice from the
heart failure team before considering their use.
- If you have recurrent hyperkalaemia (high potassium level), the amount of potassium-containing foods and supplements should be limited.
Optimize exercise tolerance
- Undertake daily and regular exercise and be physically active, such as walking, cycling, swimming, jogging, rowing or light weight exercise
- Ask your heart failure team for advice if you have questions regarding whether it is safe to exercise, and which exercises suit you best.
- Adapt physical activity to your symptoms and personal preferences.
- If possible, undertake regular exercise at a level sufficient to provoke mild or moderate breathlessness.
- For some: extreme athleticism should be avoided.
Sexual activity
- If your heart failure is stable, be reassured about engaging in sex, provided sexual activity does not provoke undue symptoms. If erectile
dysfunction is a problem, ask for advice on possible treatment.
Medication taking
- Try to engage in the management of your medication, understand the rationale, benefits and potential adverse effects of medical therapy.
- If preferred, encourage a family member to join you when your medicines are discussed.
- Ask for help if needed from family and friends.
- Discuss with your health care provider(s) anything that is hindering you from taking your medicines.
- Consider use of tools/aids to help remind you to take your tablets, such as a dosette box, electronic reminders, phone cues, etc.
- When starting heart failure medication, you may temporarily feel fatigue or tiredness; this is common, and is usually resolved after a few weeks.
- Because several heart failure medicines can cause dizziness, spacing individual drugs out at different times throughout the day may help. In case
of dizziness, it can help to elevate your legs or stand up slowly.
- To limit disturbance of daily life caused by diuretics consider taking diuretics in the morning or up to lunchtime.
- Let your health care provider know if you think you are having a side effect.
Optimize psychological status
- Try to recognize concerns and worries and try to ask for help.
- Consider attending support groups to where patients can exchange views and understandings.
- Consider talking to family and friends, or a health care provider about your concerns/worries.
- Try to be physically active, even when you feel down.
Optimize sleep
- Be aware that good sleep promotes health.
- Insomnia is common and if it occurs, begin with ‘sleep hygiene’ activities such as avoiding caffeine late in the day.
- Consider doing relaxing activities before sleep. Yoga and mindfulness in the evening can improve sleep, as can a short walk outside. Consider
avoiding TV, mobile phone, or computer use in the last hour before sleep.
- Consult your health care provider if you need to use more pillows at night due to shortness of breath (orthopnoea), suffer from recurrent
awakening during the night (paroxysmal nocturnal dyspnoea), or experience sleep apnoea.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 (Continued)
Self-care maintenance
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Adapt travel and leisure
- Plan travel and leisure activities according to symptom burden and physical capacity.
- Consider train travel instead of air travel if possible, depending on the length of travel.
- Wear compression stockings during travel when movement is curtailed.
- Discuss travel plans with the heart failure team.
- Ensure that appropriate travel insurance has been obtained.
- Take your medicines in the cabin luggage on the plane and the same amount also in the checked-in luggage, and ensure you have sufficient
quantities for the whole duration of the trip, carry a list of medication in English (dosages and the generic names) and of the device name if
relevant and obtain the list of medical centres at your destination treating patients with that same device.
- Monitor symptoms and adapt fluid intake and diuretic therapy according to humidity and altered salt intake in the diet.
- Be aware of adverse reactions to sun exposure with certain medication (such as amiodarone).
- Be aware that some airlines stipulate advance information in the case of ‘at-risk’ passengers.
- Consider local/national/international regulations related to driving with heart failure or/an implantable cardioverter-defibrillator.
- Patients in NYHA class IV are advised against driving.
Immunization and preventing infections
- Get immunization for influenza and pneumococcal disease.
Smoking and drug use
- Stop smoking (cigarettes, e-cigarettes, waterpipe).
- Do not use recreational drugs.
- Seek advice and support to stop smoking or using drugs. Encourage family members and friends to support you.
Self-care monitoring (Table 2)
- Monitor signs and symptoms of heart failure
- Monitor other symptoms such as deterioration of comorbidities and dehydration
- Monitor side effects
- Monitor response to self-care management behaviours
Self-care management
- Low blood pressure readings without symptoms are no reason for concern.
- Adjust diuretic dose according to the advice received by the heart failure management team, mainly relative to symptoms and weight variation.
- Do not hesitate to contact a health care professional if in need of support and advice.
- Ask your health care provider which strategy to apply for specific symptoms.
- Do not hesitate to contact a health care professional, e.g. your general practitioner or the heart failure team, when in doubt.
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Table 2 Changes for patients with heart failure to self-monitor
What to monitor Why monitor? Possibly related to
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Symptoms and signs
Shortness of breath /dyspnoea
During activity (walking flat, walking stairs)
Lying flat/at night
During activity
Fluid overload, increased afterload (relatively high blood pressure),
comorbidities (chronic obstructive pulmonary disease), cardiac ischaemia
Oedema (legs, hands, ankles, thighs, scrotum, waist, abdomen) Fluid overload
Chest pain Cardiac ischaemia, fluid overload, increased afterload (relatively high blood
pressure), comorbidities, anxiety
Decreased appetite/nausea Fluid overload, anxiety, renal impairment
Fatigue, tiredness Fluid overload, progression of heart failure, side effect of medication, sleep
problems, anaemia
Cough, wheezing Fluid overload, side effect of medication, comorbidities (chronic obstructive
pulmonary disease) increased afterload (relative increase in blood pressure)
Thirst Dehydration, progression of heart failure, side effect of medication (diuretics)
Palpitations Arrhythmia
Dizziness Low blood pressure (side effect), severity of heart failure, arrhythmia,
dehydration
Reduced activity level Clinical deterioration, anaemia
Weight: regularly/daily in same conditions (e.g. after morning
toilet, in light clothes), using same weighing scale
Sudden weight gain: fluid overload
Weight loss: malnutrition, sudden dehydration
Pulse Fluid overload, arrhythmia, severity of heart failure
Blood pressure Side effect of medication, hypertension/orthostatic hypotension
Other issues to monitor/assess Why monitor?
Need for support Practical and emotional support might be needed
Nutritional status/food intake To prevent malnutrition
Fever, diarrhoea, vomiting Possible need for adapting medications, fluid intake, diagnose acute
comorbidities
Depressive feelings, low mood, anxiety Possible deterioration, need for support
Response to self-care management behaviours Possible need to confirm or change reactions to symptoms in future
Table 3 Self-monitoring of signs and symptoms with telemonitoring devices (invasive and non-invasive)
Weight Sudden weight gain: fluid overload
Sudden weight loss: hypovolaemia
Pulse Fluid overload, arrhythmia, severity of heart failure
Lung impedance Fluid overload, hypovolaemia
Blood pressure Side effect of medication, hypertension/orthostatic hypotension
Pulmonary artery pressure Fluid overload, increased afterload
Activity monitor Severity progression of heart failure, comorbidities
Oxygen saturation Fluid overload, comorbidities (chronic obstructive pulmonary disease)
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